F-1: Purple Biotech Launches $6M Public Offering of ADSs and Warrants

Purple Biotech Ltd. announced a public offering of up to 2,702,702 American Depositary Shares and accompanying warrants, aiming to raise approximately $5.18 million in net proceeds for oncology therapeutic development and general working capital.

Summary

• Offering up to 2,702,702 American Depositary Shares (ADSs), each representing 200 ordinary shares, and up to 5,405,404 Series B Warrants.
• Pre-Funded Warrants are available for purchasers whose beneficial ownership would exceed 4.99% (or 9.99%) of outstanding ordinary shares.
• The assumed combined public offering price is $2.22 per ADS and accompanying Warrants, based on the Nasdaq closing price on August 27, 2025.
• Net proceeds are estimated at approximately $5.18 million, assuming the maximum sale and no Pre-Funded Warrants or Warrant exercises.
• Proceeds will be used to fund the development of oncology therapeutic candidates and for general working capital and corporate purposes.
• The company is a clinical-stage biotechnology firm focused on developing therapies to overcome tumor immune evasion and drug resistance, with a pipeline including CAPTN-3, CM24, and NT219.
• CAPTN-3's lead tri-specific, IM1240, is in preclinical development, targeting the 5T4 antigen, with an IND application expected in 2026.
• CM24, a humanized monoclonal antibody, completed a Phase 2 study for pancreatic ductal adenocarcinoma (PDAC), demonstrating consistent improvement across efficacy endpoints and identifying potential predictive biomarkers. A Phase 2b study is planned upon partnering or sufficient investment.
• NT219, a dual inhibitor small molecule, completed a Phase 1 study and an investigator-initiated Phase 2 study was initiated in June 2025 for recurrent/metastatic squamous cell carcinoma of the head and neck.
• The offering is on a 'reasonable best efforts basis' with no minimum offering amount, meaning the company may not sell all securities or receive the maximum proceeds.

Sentiment

Score: 4

Explanation: While the company has a promising oncology pipeline with several candidates in clinical and preclinical stages, the 'best efforts' offering structure with no minimum, significant potential dilution, and ongoing need for substantial future financing introduce considerable risk. The likely PFIC status for U.S. investors is also a deterrent. The positive clinical progress is overshadowed by the financing structure and financial risks.

Positives

• Advancement of a diverse oncology pipeline with three therapeutic candidates: CAPTN-3 (IM1240), CM24, and NT219.
• CM24's Phase 2 study for pancreatic ductal adenocarcinoma showed consistent improvement across all efficacy endpoints and identified potentially predictive biomarkers.
• NT219 demonstrated anti-tumor activity in its Phase 1 study, and an investigator-initiated Phase 2 study has commenced.
• A pre-IND meeting with the FDA provided a clear path forward for CAPTN-3 (IM1240) development through Phase 1, with an IND submission expected in 2026.
• The offering aims to secure capital to fund ongoing and future development of therapeutic candidates and general working capital.

Negatives

• The offering is on a 'reasonable best efforts basis' with no minimum, meaning the company may not raise sufficient capital to meet its business goals, and investors will not receive a refund if insufficient capital is raised.
• New investors will experience immediate and substantial dilution of approximately $0.50 per ADS based on the assumed offering price.
• There is no established public trading market for the Pre-Funded Warrants or Series B Warrants, which will limit their liquidity.
• The company has incurred losses since its inception and will require significant additional financing in the future, which may not be available on acceptable terms.
• Future equity financings are likely to be dilutive to existing stockholders.
• The company believes it will likely be treated as a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes for 2024, which can result in adverse tax consequences for U.S. holders.
• No cash dividends are anticipated in the foreseeable future; investors must rely on share price appreciation for any return on investment.
• Political, economic, and military instability in Israel and its region may adversely affect business operations, despite no material impact since October 2023.
• Commercial insurance does not cover losses from Middle East security events, and government coverage may not be sufficient to fully compensate for damages.

Risks

• Investing in the company's securities involves a high degree of risk.
• Management will have broad discretion over the use of net proceeds, and may not use them effectively.
• The 'best efforts' nature of the offering means the company may not raise the maximum proceeds, potentially hindering its ability to execute business plans.
• There is no minimum offering amount, so investors will not receive a refund if insufficient capital is raised.
• New investors will experience immediate and substantial dilution in the net tangible book value per ADS.
• There is no public market for the Warrants or Pre-Funded Warrants, limiting their liquidity and making them speculative.
• Holders of Warrants and Pre-Funded Warrants will not have ADS ownership rights until exercise.
• Purchasers who enter into a securities purchase agreement may have rights not available to other purchasers.
• The sale of a substantial percentage of outstanding Ordinary Shares (up to 89% of pre-offering shares, plus 178% underlying warrants) could cause the price of ADSs and/or Ordinary Shares to decline.
• Future equity offerings may lead to further dilution for existing shareholders.
• U.S. holders of ADSs may suffer adverse tax consequences if the company is characterized as a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes.
• The company does not anticipate paying cash dividends, requiring investors to rely on share price appreciation.
• Political, economic, and military instability in Israel and its region may adversely affect the company's business, results of operations, and financial condition.
• Commercial insurance does not cover losses from Middle East security events, and government coverage may not be sufficient.
• The global perception of Israel and Israeli companies, influenced by international judicial bodies, may lead to increased sanctions and other negative measures.
• Parties with agreements involving performance in Israel may claim force majeure due to the security situation.
• A growing movement to boycott Israeli goods and services could adversely impact the company's business.
• Military service call-ups of Israeli military reservists could materially and adversely affect the company's business, prospects, financial condition, and results of operations.
• Political conditions within Israel, such as proposed judicial system changes, may affect the Israeli economy and, in turn, the company's business and share price.

Future Outlook

The company intends to use the net proceeds from this offering to fund the development of its oncology therapeutic candidates and for general working capital and corporate purposes. It expects to submit an Investigational New Drug (IND) application to the FDA for IM1240 during 2026 and plans to initiate a first-in-human study thereafter. A Phase 2b study for CM24 is planned upon securing a partnership or obtaining sufficient investment.

Management Comments

• Management will have broad discretion in the application of the net proceeds from this offering.

Industry Context

The company operates in the clinical-stage oncology biotechnology sector, focusing on novel therapies to address tumor immune evasion and drug resistance. This aligns with broader industry trends emphasizing targeted therapies and immunotherapies. The pipeline, including tri-specific antibodies (CAPTN-3), monoclonal antibodies (CM24), and small molecule inhibitors (NT219), reflects a diversified approach to cancer treatment. The need for additional financing, particularly through equity offerings, is common for clinical-stage biotech companies that typically incur significant R&D expenses without substantial revenue generation.

Comparison to Industry Standards

• The 'best efforts' offering structure with no minimum proceeds is less favorable than a firm commitment underwriting, often indicating higher perceived risk or smaller market interest compared to more established companies.
• The immediate dilution of $0.50 per ADS for new investors, relative to an assumed offering price of $2.22, represents a substantial dilution, suggesting a high cost of capital for the company.
• The absence of a public trading market for the newly issued Warrants and Pre-Funded Warrants is standard for such instruments but limits investor liquidity, which is a common characteristic in offerings by smaller growth companies.
• The company's likely classification as a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes is a significant negative factor, as it can complicate tax treatment for U.S. investors and may deter some institutional investors, a common issue for non-U.S. companies with limited active income.

Corporate Governance

Legal Proceedings

• The company expects to indemnify Isaac Israel for obligations, including deductibles for its directors and officers liability insurance policy, and may be required to pay costs and expenses related to the 'Atzmon Claim' described in its 2024 Annual Report (incorporated by reference).

Related Party Transactions

• No officers, directors, or employees are currently party to any material transaction with the company or its subsidiaries (exceeding $120,000), other than for services as employees, officers, and directors, reimbursement for expenses, and other employee benefits (e.g., stock options, RSUs).

Stakeholder Impact

• **Shareholders**: Face potential significant dilution from the current offering and future capital raises. Their return on investment will primarily depend on share price appreciation, as no cash dividends are anticipated. U.S. holders may experience adverse tax consequences due to the company's likely PFIC status.
• **New Investors**: Will experience immediate and substantial dilution. Those purchasing Warrants or Pre-Funded Warrants will face limited liquidity due to no established public trading market for these instruments.
• **Employees**: Potential for disruption or absence due to military service call-ups in Israel, which could affect operations.
• **Company Operations**: The proceeds from the offering are crucial for funding the development of oncology therapeutic candidates and for general working capital, directly impacting the company's ability to advance its pipeline and sustain operations.
• **Creditors**: The company's ability to satisfy existing and foreseeable obligations is a factor in dividend distribution decisions under Israeli law, and the capital raise aims to improve financial stability.

Next Steps

• Submit an Investigational New Drug (IND) application to the FDA for IM1240 during 2026.
• Initiate a first-in-human study for IM1240 thereafter.
• Plan to initiate a Phase 2b study for CM24 upon securing a partnership or obtaining sufficient investment.
• The offering will terminate on October 3, 2025, unless terminated earlier by the company.
• Delivery of the Securities to purchasers is expected to be made on or about the date of the prospectus (placeholder).

Key Dates

Recommendation

While the company has a promising oncology pipeline with several candidates in clinical and preclinical stages, the current 'best efforts' offering structure, significant potential dilution, and ongoing need for substantial future financing introduce considerable risk. The likely PFIC status for U.S. investors is also a deterrent. Investors should hold to monitor the success of the capital raise and the progress of the clinical programs, particularly the planned Phase 2b for CM24 and IND submission for IM1240, before making further investment decisions. The current offering is primarily a financing event to sustain operations and development rather than a clear value-creation event.

Keywords

Purple Biotech, ADS offering, warrants, biotechnology, oncology, clinical-stage, CAPTN-3, CM24, NT219, cancer therapy, immune evasion, drug resistance, Nasdaq, Tel Aviv Stock Exchange, equity financing, dilution, risk factors, Israel, PFIC, F-1 filing